Stem cell transplantation, using high-dose chemotherapy with or without TBI, is usually associated with significant nausea and vomiting. A variety of antiemetic regimens have been studied to control nausea and vomiting associated with the preparative therapy phase of SCT. We review the most significant studies and highlight the limitations of many of these studies. In addition, we review the few studies with the use of aprepitant as an antiemetic in combination with a 5HT 3 antagonist and a steroid. The American Society of Clinical Oncology guideline for antiemetic use for treatment regimens that are highly emetogenic is reviewed regarding recommendations for SCT preparative regimens. On the basis of this review of published data, we recommend the basic outline for an effective antiemetic investigational approach to the study and to the control of nausea and vomiting during the preparative phase of treatment for SCT.
Introduction
High-dose chemotherapy, often combined with TBI or total nodal irradiation of a varied amount, and stem cell rescue is a treatment modality applied to a wide variety of medical conditions. 1 The delivery of high-dose therapy is almost always associated with a great degree of nausea and vomiting. 2 A number of studies have been published regarding control of nausea and vomiting during the time when such therapy is delivered up until or shortly after the stem cell infusion. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Variable degrees of success regarding control of nausea and vomiting have been reported, with many agents, including serotonin antagonists such as granisetron and ondansetron. Often, patients undergoing these therapies with high-dose chemotherapy, with or without radiation, have had a long history of similar types of therapy with variable control of nausea and vomiting.
In this review, key studies over the past 15 years will be cited along with the results and problems indicated with the analyses of the results from these studies. Results will be discussed in the context of the American Society of Clinical Oncology (ASCO) guidelines for control of nausea and vomiting. 2 Owing to the lack of guidelines as to how antiemetics should be used in the context of stem cell preparative regimens, physicians, nurses and other health care professionals are often left to devise their own antiemetic regimens for their patients.
Materials and methods
A review of the key studies was made from 1990 to 2007 by searching Medline (Table 1) . The definitive studies identified were abstracted and reviewed to discuss the type of study, study drug(s), form of administration of the antiemetic medications, types of transplants studied and results/outcomes. Only studies that were specifically focused on patients undergoing SCT were reviewed, although some SCT patients may have been part of a larger series of patients undergoing treatment with other antiemetic combinations. The cutoff for review was in 1990 because the generation of the 5-HT 3 serotonin antagonists after that time began an era in oncology of more focused control of emesis for all forms of cancer-related chemotherapy and radiation. Although many drugs were prescribed before 1990 to control chemotherapyinduced nausea and vomiting (CINV), many of which still remain in use today (for example, dexamethasone and metoclopramide), the mechanism of action of these drugs is not directed against a mediator of CINV. 5HT 3 antagonists were not available before 1990, and thus control of nausea and vomiting was not as well addressed. Thus, only published studies since 1990 were reviewed.
Results
Incidence of emesis with type of transplant Adel et al. 19 completed a retrospective review of patients admitted to the adult BMT unit at Memorial SloanKettering to analyze the rate of nausea and vomiting. This 2006 study established that autologous transplants are associated with less nausea and vomiting (51 and 18%, respectively) than allogeneic transplants (78 and 39%, respectively). Patients receiving radiation had a higher incidence of nausea and vomiting (81 and 33%, respectively) versus the those not receiving radiation as part of their preparative therapies (51 and 20%, respectively). Of all disease groups, patients with leukemia had the highest incidence of nausea (85%) and vomiting (45%). These data helped to establish that, in a single institution, the baseline incidence of nausea and vomiting differed depending on the transplant type and transplant preparative therapy. Only a small number of the transplant studies reviewed included patients undergoing allogeneic transplantation.
Single-arm 5HT 3 antagonists studies A number of reports have been published as single-arm studies to assess success rates of controlling nausea and vomiting. Barbounis et al. 4 reported on the use of ondansetron administered intravenously from day À6 to day þ 1 post-autologous stem cell infusion. Although there was a reported 76% protection rate (complete and major protection, o2 emetic episodes per day) on day 1 of chemotherapy administration, there was a progressive decline in controlling vomiting and nausea during subsequent days of chemotherapy administration. As the effects of the chemotherapy diminished, the efficacy of the antiemetics improved at controlling the nausea and vomiting.
Two single-arm studies assessed the efficacy of tropisetron, a newer 5HT 3, not available in the United States at present. In the first of these studies, Or et al.
3 used tropisetron at 5 mg once daily on the days when chemotherapy was administered and when radiation was given. There was complete or major control of emesis on day 1, and by day 5, emesis control was still found in 480% patients. Barbounis et al. 11 also analyzed the use of tropisetron with additional dexamethasone. He found that 83% of patients had complete or major protection on day 1, but decreasing protection on the subsequent days. Of the patients, 35% were protected from vomiting during the entire treatment period. Both studies included small numbers of patients (n ¼ 11 in Or study and n ¼ 31 in the Barbounis study), and both included mixtures of patients with a variety of malignancies undergoing either autologous or allogeneic transplants using varied preparative therapies.
Another single-arm study using a different 5HT 3, dolasetron mesylate, analyzed 20 patients, all receiving the same preparative chemotherapy and TBI, and all received an allogeneic transplant. 8 A total of 65% of patients had good emesis control (two or fewer emetic episodes on each day of TBI) and 55% on day 1 of chemotherapy. Emesis control was good acutely, but delayed emesis was not well controlled according to the study report. Thus, these single-arm studies indicated the need for regimens that provided better acute and delayed emesis control.
Comparative studies of different 5HT 3 antagonists on similar groups of patients Comparisons of ondansetron and granisetron have been reported by several groups, each using different dosing formulas and administration routes. In a study of 197 patients, including pediatric patients, from the University of Minnesota, continuous infusion ondansetron was compared with every 12-h dosing with granisetron. 12 Antiemetics were given through day zero to patients with a variety of diseases undergoing autologous, matched allogeneic and unrelated transplants. A total of 61-63% of patient-days through day 0 were without vomiting, supporting the conclusion of a high rate of success with these doses and administration routes over previously published regimens. However, there was still a sizeable percentage of patients who experienced vomiting acutely and over the delayed period of time.
In a smaller study (n ¼ 34), oral ondansetron and oral granisetron were given to a patient group in which all Table 1 Synopsis of studies reviewed received the same radiation but with a variety of conditioning therapies. 13 Patients in the granisetron group had a 33.3% control of vomiting versus 26.7% control in the ondansetron group. Their conclusion was that more optimal therapy was needed.
In a third study that was reviewed, patients (n ¼ 96) were randomized to receive granisetron or ondansetron intravenously.
14 All patients received dexamethasone and lorazepam. On day 1, more than 90% of the patients had control of emesis with these regimens but daily control of all end points decreased, with loss of efficacy for both agents by day 6 after the start of the preparative therapy. By day 6, only 46-50% of the patients had complete control of vomiting, again supporting the need for a regimen with better control. In this study were patients with a variety of different diagnoses who received a variety of preparative therapies.
Varying regimens of continuous-infusion 5HT 3 antagonists A three-arm study reported results comparing two different continuous-infusion ondansetron doses with a regimen of metoclopramide plus droperidol. 5 Analyses were completed from the second day of cyclophosphamide because the incidence of nausea and vomiting was highest on that day. By the end of the study, 30% had failed on low-dose ondansetron, 60% on high dose ondansetron and 44% on the metoclopramide arm, again demonstrating the need for antiemetic regimens that provide better emesis control. Another study analysing intermittent versus continuous ondansetron in 66 patients undergoing autologous transplants for breast cancer found no difference in the outcome: emesis control was not statisfactory. 10 Good acute control but with late-onset delayed emesis With a combination of oral granisetron, oral prochlorperazine and oral dexamethasone, Frakes et al.
7 demonstrated very good acute control (97, 92, 86, 78 and 75% for days À4, À3, À2, À1 and 0). One-third of the patients who had not failed during the first 5-day study period had severe late-onset emesis during the 8 days following reinfusion of the stem cells. Although the acute emesis control was excellent, again a sizeable percentage had late-onset emesis.
Aprepitant use over a prolonged period of time in combination Bubalo et al. 20, 21 have presented preliminary information of a randomized, placebo controlled trial evaluating the addition of aprepitant to a standard antiemetic regimen. This study included 40 patients, 21 divided between the group with a 5HT 3 , steroid and placebo versus the group with aprepitant replacing the placebo. Most of the patients underwent an allogeneic transplant but with either a cyclophosphamide-TBI or a busulfan-cyclophosphamide preparative regimen. The aprepitant or placebo were given for 10-12 days, covering the entire period of the preparative therapy and extending to the point 4 days post-infusion of the hematopoietic stem cells. A total of 17 patients in the aprepitant group had a complete response (no emesis, mildto-moderate nausea) or a major response (no emesis with severe nausea or 1-2 emeses on 1 day only) compared with 9 in the placebo group (P ¼ 0.025). The authors concluded that even with two different preparative therapies, the aprepitant addition provided an improvement for emesis control in this population of patients.
Szer et al. 18 reported a single-arm pilot study with aprepitant given through to day 7 after the hematopoietic SCT or discharge. Of the 14 patients, 7 had total control of nausea and vomiting the first week after HSCT, and 11 patients had total control in the second week after HSCT. With a single-arm study, it was difficult with these data to know how much aprepitant improved the clinical response.
A retrospective chart review reported by Barnett et al. 15 looked at efficacy of aprepitant in 41 autologous transplant patients. There was a reduced number of nausea episodes in the acute and delayed phase, and emetic episodes were also reduced in the aprepitant group; however, again it was difficult to know how much aprepitant improved the clinical response. Junagadhwalla et al. 16 analyzed the tolerability of aprepitant given for a longer period of time (average 7.6 days) in a group of patients undergoing an autologous transplant. He found that aprepitant can be used safely without adding to the toxicity of the chemotherapy that was administered.
Discussion

Pathophysiology of emesis and the active sites of antiemetic drugs
The primary action site of 5HT 3 receptor antagonists is at the abdominal vagal afferents (Figure 1) . 22 Cytotoxic agents and other toxins increase release of serotonin, which subsequently activates 5HT 3 receptors. This signal to the serotonin receptors associated with vagal afferents is abolished by 5HT 3 antagonists such as granisetron and ondansetron. 22 Neurokinin NK1 receptor antagonists, on the other hand, have shown a broad spectrum of action treating diverse causes of nausea and vomiting. They are thought to work at the dorsal vagal complex in the medulla, inhibiting the response that results in gastric emptying. 22 The major psychoactive component of marijuana, tetrahydrocannabinol, may work to control emesis by direct relaxation of the stomach fundus. 22 A variety of other neurotransmitters are involved in CINV and the emetic reflex including dopamine, acetylcholine, endorphins, gamma-aminobutyric acid and histamine. [23] [24] [25] Many of the other agents used to control CINV target the release of these other substances, which then trigger the emetic reflex. However, other agents such as steroids have an unknown mechanism controlling CINV, particularly in the clinical situation of highly emetogenic cisplatin during which some patients benefit from steroids alone. 26 
Study of antiemetic drugs in SCT patients
Constructing a study of antiemetic control in a population of patients undergoing SCT is a difficult process, particularly if the study includes only patients from a smaller center from which it would be difficult to obtain a large number of patients with the same underlying disease, receiving the same kind of preparative therapy for the same kind of malignancy. In the large-scale studies of the efficacy of antiemetics in the non-transplant population, most include patients with a single disease, undergoing therapy with a single protocol of chemotherapy and utilizing the same antiemetic regimen. 27 In these latter studies, the study medication is not ordinarily permitted to be used as a rescue medication, and many of the confounding factors detailed above are not relevant.
Problems identified in the studies reviewed
From the studies reviewed, we can observe the following: (1) most of the reported studies in BMT patients analyzed all together patients with a variety of diagnoses, receiving either autologous or allogeneic stem cells and receiving a variety of preparative therapies; (2) most studies did not include chemotherapy-naive patients in whom control of nausea and vomiting may be quite different than other oncology-experienced patients; (3) few studies excluded patients with a recent history of nausea or vomiting; (4) although some of the reviewed reports indicated that the results were excellent for the control of acute nausea and vomiting in a mixture of patients, few analyzed reports of delayed nausea or vomiting. Those studies that analyzed the period post-infusion of stem cells to assess nausea and vomiting documented a decrease in the efficacy of the antiemetics provided; (5) none of the reports indicated whether steroids, often administered to BMT patients (for example, premedications for blood transfusions, stem cell infusions, antifungals or antimicrobials associated with febrile reactions), were permitted in the study period; likewise, we have no information on whether antihistamines were permitted or given during the study periods; (6) single-center studies are often limited by patient numbers and this was apparent by the number of studies with fewer than 50 patients or studies analysing uniform populations of patients with the same disease and identical preparative therapies. As documented in the retrospective study by Adel et al. 19 , there is an apparent difference in the incidence of nausea and vomiting between transplant types, patient diagnoses and with the use of TBI; (7) no study reported data on the effect of adequate control of nausea and vomiting in the period post-infusion of stem cells to determine if initial control of nausea and vomiting had an effect on subsequent alimentation and discharge from the SCT unit and/or hospital; and (8) finally, no study assessed the cryo-protectants/preservatives in which stem cells have been suspended to determine their emetic potential.
Factors that come into consideration for SCT patients There are many factors that are important to consider for those undergoing SCT when studying the incidence of nausea and vomiting. The preparative therapy, which may be chemotherapy alone or a combination of chemotherapy and TBI or a variant thereof, results in significant gastrointestinal disruption that may last for days to weeks. Disruption of the gastrointestinal tract may result in a continual source of serotonin release. This continued source of serotonin and the release of substance P may serve as a constant stimulus to nausea and vomiting. Transplant patients have past records of varied nutrition support, varied history of nausea, vomiting and sometimes anticipatory vomiting, variable use of antiemetic regimens, and a variety of current and past infections.
2 Often, SCT patients will then have different health care providers at different centers, with different regimens for controlling nausea and vomiting. These factors may make it difficult to control anticipatory nausea and vomiting or prevent nausea and vomiting from the planned preparative therapy.
Antiemetic guidelines
The American Society of Clinical Oncology guidelines contain no explicit recommendation for use of antiemetics with such preparative therapies. 2 However, in the ASCO guidelines for the control of emesis associated with chemotherapy, there is the suggestion that all preparative therapies for SCT fall into the category of highly emetogenic chemotherapy. Thus, patients should receive the recommended antiemetic control as given to other patients receiving similar highly emetogenic chemotherapy treatments. 2 Control of delayed emesis For many patients, post-infusion of stem cells, nausea and vomiting persisted and the effect of the antiemetics administered during the time of the preparative therapy diminished. Following infusion of stem cells, multiple other factors may have an effect on the patient, including damage to the gastrointestinal lining, delayed effects of radiation, 26 multiple types of infection from viral to bacterial or fungal, diarrhea, profound neutropenia, prophylactic antimicrobials, GVHD and organ failure. Radiation in particular may result in cortical swelling, irreversible tissue destruction and cytokine release that result in a prolonged stimulus of delayed emesis. 28, 29 Thus, it becomes very difficult to study the effect of antiemetics during the post transplant phase of treatment with so many confounding factors.
Triple antiemetic regimens
Several protocols are in place looking at the triple antiemetic combination (steroid combined with a 5-HT 3 antagonist and aprepitant) for those undergoing SCT preparative therapy, but the reported results are preliminary. 21 The Bubalo study from Oregon included a novel way of giving a prolonged course of aprepitant (10-12 days, including the preparative therapy period and for several days after the infusion of the stem cells). 21 In the meantime, ASCO guidelines suggest the use of this triple combination for such therapy as one would give for highly emetogenic chemotherapy. 2 However, we have minimal data for assessing the success of this combination in a large population of patients.
The need for further trials
The ideal study to assess efforts to control emesis during preparative therapy should include patients receiving the same preparative therapy and the same type of transplant. The study should control for patients with chronic nausea and vomiting pretransplant (not include patients with a history of anticipatory nausea and vomiting) and control for the use of steroids for blood products and antifungal or other premedication purposes (so that patients are not receiving extra steroids beyond those that may be included in the antiemetic regimens employed). Patients should be monitored up until the time of the stem cell infusion. At the point of the stem cell infusion, a number of premedications are often given that will confound the analysis, and even cryo-preservative agents used in autologous products may have an effect on nausea and vomiting. Thus, studies need to consider the effects of such agents on the rising incidence of nausea and vomiting that may be seen on the day of the stem cell infusion and the following days. Several studies have reported good to excellent control of acute nausea and vomiting, and with the use of aprepitant, the problem of delayed nausea and vomiting may begin to be addressed.
The majority of preparative regimens for SCT are 5-10 days in duration and are, in particular, longer than 5 days when TBI is included. Recent presentations of pilot studies with shorter preparative regimens showed control of acute emesis but still rates of delayed nausea and vomiting in the 30-60% range, treated with 1-3 doses of palonosetron. 30, 31 Thus, a two-armed study might include one of the reported excellent regimens for control of acute nausea and vomiting with an investigational arm including an NK1 antagonist. The investigational arm should maximize coverage for delayed nausea and vomiting by using two doses of palonosetron combined with an NK1 antagonist given for multiple days, as in the Bubalo studies. Initial investigations suggest that substance P levels continue to rise after highly emetogenic chemotherapy; 24, 32 daily doses of an NK1 receptor antagonist through day 4 following the stem cell infusion may help to counteract the delayed effects of the events occurring up to the day of the stem cell infusion, as in the Bubalo studies. 20, 21 Minimizing CINV should be a reasonable goal for those receiving these highly emetogenic therapies. 26 Complete control may not be possible in these settings of high-dose chemotherapy with TBI just yet as they should be in the settings of those receiving more standard emetogenic chemotherapy, but further investigations are warranted.
